Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.32−0.06 (-2.52%)
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Protara Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Protara Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$31.49M. For fiscal 2016 it was -$28.58M. The highest annual figure on record is -$7.10M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | -$28.58M | – |
| FY2015 | Dec 31, 2015 | -$20.81M | – |
| FY2014 | Dec 31, 2014 | -$7.55M | – |
| FY2013 | Dec 31, 2013 | -$7.10M | – |
| FY2012 | Dec 31, 2012 | -$7.94M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2017 | Sep 30, 2017 | -$12.27M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.13M | – |
See a number that looks wrong?